|本期目录/Table of Contents|

[1]安林静,张 昕,黄加干,等.阶梯式管理对院外晚期肝细胞癌患者服用仑伐替尼的影响[J].传染病信息,2019,05:441-444.
 AN Lin-jing,ZHANG Xin,HUANG Jia-gan,et al.Effect of step-wise management on lenvatinibtaken by the patients with advanced hepatocellular carcinoma out of hospitals[J].Infectious Disease Information,2019,05:441-444.
点击复制

阶梯式管理对院外晚期肝细胞癌患者服用仑伐替尼的影响(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年05期
页码:
441-444
栏目:
论著
出版日期:
2019-11-13

文章信息/Info

Title:
Effect of step-wise management on lenvatinibtaken by the patients with advanced hepatocellular carcinoma out of hospitals
文章编号:
1007-8134(2019)05-0441-04
作者:
安林静张 昕黄加干郝莉燕黄 顺沙花燕杨 滢王亚东周渝霞
100039北京,中国人民解放军总医院第五医学中心 护理部(安林静、张昕、郝莉燕、黄顺、沙花燕、杨滢、王亚东), 肝脏肿瘤中心(黄加干),医学信息中心(周渝霞)
Author(s):
AN Lin-jing ZHANG Xin HUANG Jia-gan HAO Li-yan HUANG Shun SHA Hua-yan YANG Ying WANG Ya-dong ZHOU Yu-xia*
Department of Nursing, the Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
关键词:
晚期肝细胞癌院外护理肝性脑病
Keywords:
advance hepatocellular carcinoma out-hospitals nursing care hepatic encephalopathy
分类号:
R473.73
DOI:
10.3969/j.issn.1007-8134.2019.05.016
文献标识码:
A
摘要:
目的探讨院外晚期肝细胞癌( hepatocellular carcinoma, HCC)患者服用仑伐替尼治疗的新型护理管理模式,实现减少因仑伐替尼相关显性肝性脑病而中断或终止仑伐替尼治疗的病例。方法采用单中心随机对照研究,评价以微信为媒介的闭合阶梯式护理管理院外晚期 HCC患者服用仑伐替尼治疗的可接受性效果,以显性肝性脑病中断或终止仑伐替尼治疗为主要终点。结果阶梯式护理管理组晚期 HCC患者服用仑伐替尼 12周内肝性脑病的诊断率为 60.0%,明显高于家庭管理组的 20.0%(P< 0.05);经有效护理干预,阶梯式护理管理组持续服用仑伐替尼患者达 93.3%,高于家庭管理组的80.0%;尤其因显性肝性脑病终止仑伐替尼治疗的病例患者仅为 6.7%,低于家庭护理组的 20.0%。结论阶梯式护理管理院外晚期 HCC患者服用仑伐替尼治疗可早期判定肝性脑病,是减少因仑伐替尼相关肝性脑病中断或终止治疗事件,延长晚期 HCC患者生存期的必要手段。
Abstract:
ObjectiveTo develop a novel taking lenvatinib nursing management pattern for the patients with advancedhepatocellular carcinoma out of hospitals and reduce the number of case suspended or terminated due to lenvatinib-related overthepatic encephalopathy. MethodsA single-center randomized controlled trial was conducted to assess the acceptability ofclosed step-wise nursing management in patients with advanced hepatocellular carcinoma taking lenvatinib out of hospitals, taking WeChat as the medium. The primary endpoint was the discontinuation or termination of lenvatinib treatment due to overt hepaticencephalopathy. ResultsIn step-wise nursing management group, the diagnostic rate of hepatic encephalopathy in patients withadvanced hepatocellular carcinoma within 12 weeks after lenvatinib treatment was 60.0%, which was obviously higher than that infamily caregiver group 20.0% (P< 0.05); after effective nursing intervention, 93.3% of the patients in step-wise nursing management group continued taking lenvatinib, which was higher than that in family caregiver group (80.0%); especially. The discontinuationof lenvatinib treatment due to overt hepatic encephalopathy was only 6.7%, which was lower than that in family caregiver group (20.0%). ConclusionsStep-wise nursing management can predicate hepatic encephalopathy at early phase in patients with advanced livercancer taking lenvatinib out of hospitals. It is the necessary means to reduce the discontinuation or termination of lenvatinib treatment due to lenvatinib-related hepatic encephalopathy, and prolong the life of patients with advanced hepatocellular carcinoma.

参考文献/References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3] 刘淦,孙杰,张婷,等. 晚期肝细胞癌靶向治疗及个性化治 疗的现状[J]. 传染病信息,2019,32(2):103-118.
[4] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
[5] Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J]. J Gastroenterol, 2017, 52(4):512-519.
[6] Coolbrandt A, Wildiers H, Aertgeerts B, et al. Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapyrelated symptoms at home[J]. BMC Nurs, 2018, 17:28.
[7] 安林静,张昕,张丽娜,等. 尿素乳膏护理干预索拉非尼相 关手足皮肤反应随机对照研究[J]. 实用临床医药杂志, 2014,18(22):45-47.
[8] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4):835-853.
[9] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000, 92(3):205-216.
[10] Annemarie C, Hans W, Bert A, et al. Systematic development of chemosupport, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home[J]. BMC Nursing , 2018 17(1):28-38.
[11] Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment[J]. Semin Radiat Oncol, 2003, 13(3):176-181.
[12] 徐小元,段忠平,丁慧国,等. 肝硬化肝性脑病诊疗指南[J]. 传染病信息,2018,31(5):403-420.
[13] Bajaj JS, Heuman DM, Stering RK, et al. Validation of encephalapp, smartphone-based stroop test, for the diagnosis of covert hepatic encephalopathy[J]. Clin Gastroenterol Hepatol, 2015, 13(10):1828-1835.

备注/Memo

备注/Memo:
[基金项目]国家重大专项基金资助项目(2008ZX10002-018); 首都临床特色重点基金资助项目(Z151100004015221)
[作者单位]100039北京,中国人民解放军总医院第五医学中心 护理部(安林静、张昕、郝莉燕、黄顺、沙花燕、杨滢、王亚东), 肝脏肿瘤中心(黄加干),医学信息中心(周渝霞)
[通信作者]周渝霞,E-mail:zhouyx6@sina.com
*Correspondingauthor,E-mail:zhouyx6@sina.com
更新日期/Last Update: 2019-11-13